Navigation Links
A Biologic Drug Superior to Spiriva in Reducing COPD-Related Exacerbations Would Earn a Higher Patient Share in Europe Than in the U.S.
Date:1/12/2009

Spiriva Will Remain the Gold Standard Treatment Through 2017, According to a New Report from Decision Resources.

WALTHAM, Mass., Jan. 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a biologic drug that is superior to Boehringer Ingelheim/Pfizer's Spiriva in reducing yearly COPD-related exacerbations would earn a higher patient share in Europe (30 percent) than in the U.S. (15 percent) according to surveyed European and U.S. pulmonologists. COPD-related exacerbations are episodic events often requiring hospitalization.

"A biological drug that provides fewer yearly COPD-related exacerbations compared to current therapies holds much commercial promise," said Regina Jammen, M.S., analyst at Decision Resources. "Enthusiasm from U.S. and European pulmonologists for a biologic drug with the potential to dramatically reduce yearly exacerbation rates likely reflects physicians' recognition of not only the long-term therapeutic benefits of such a drug, but also its economic benefits."

The new report entitled Chronic Obstructive Pulmonary Disease: Blockbuster Potential Exists for Biologic Drugs That Dramatically Reduce Exacerbation Rates finds that Spiriva will remain Decision Resources' clinical gold standard treatment for COPD over the next eight years even though emerging drugs such as Forest/Almirall's aclidinium, Novartis's indacaterol, Boehringer Ingelheim's BI-1744/tiotropium and Nycomed/Mitsubishi Tanabe's roflumilast will offer therapeutic benefits to COPD patients.

About the Report

Chronic Obstructive Pulmonary Disease: Blockbuster Potential Exists for Biologic Drugs That Dramatically Reduce Exacerbation Rates is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need,
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Biologic treatment for rheumatoid arthritis and the risk of cancer
2. Thomson Scientific Announces BONDplus for Biological Researchers
3. Neurobiological Technologies Reports Going Concern Qualification
4. Neurobiological Technologies, Inc. Announces Receipt of Determination Letter from NASDAQ
5. Promising Phase 3 trial results show biologic therapy ustekinumab significantly improved psoriasis
6. Study questions assumptions about human sensitivity to biological motion
7. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
8. Neurobiological Technologies Announces Compliance With Nasdaq Listing Standards
9. Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
10. Dr. Warren Wasiewski Appointed Chief Medical Officer of Neurobiological Technologies, Inc.
11. CalbaTech Reports That LifeStems Biologics License Has Been Renewed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... 2015 , ... OncLive®’s extensive roster of Strategic ... Cancer Center (JCCC) mutually agreed to collaborate on projects that promote groundbreaking ... groups will help spread the news about the center’s leading-edge cancer research, robust ...
(Date:7/30/2015)... ... July 30, 2015 , ... Glidewell Laboratories, industry-leading provider of ... magazine, its multimedia publication focused on implant dentistry, is now available in print ... 6, Issue 2, as well as past issues of the dental laboratory’s quarterly ...
(Date:7/30/2015)... ... ... On July 23rd Clay Today Online reported the state of ... prison system, which has amassed largely enough throughout the years. Florida is the third ... Obama’s recent reduction of non violent drug offender’s prison sentences, Florida is beginning to ...
(Date:7/30/2015)... ... 30, 2015 , ... Gummy smile surgeon, Dr. Alex Farnoosh, now ... as well as the patented gum depigmentation treatmet. Dr. Farnoosh is a renowned dentist ... patients from around the world. , “Like treatment of any other disease or condition, ...
(Date:7/30/2015)... ... ... New research finds some distinct differences in the way mesothelioma behaves in younger ... website. , Researchers with the National Institutes of Health, the FDA, and the ... between 1990 and 2010. Two percent of these cases (207) occurred in people younger ...
Breaking Medicine News(10 mins):Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 3Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 4Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 4Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 3Health News:Gummy Smile Dentist, Alex Farnoosh DMD, is Now Offering Comprehensive Treatment Options for Gummy Smiles 2Health News:Study Finds Mesothelioma Behaves Differently in Younger People, According to Surviving Mesothelioma 2
... LEVERKUSEN, Germany and WEST HAVEN, Conn., Nov. 5 ... Drugs and,Medical Devices (BfArM), the U.S. Food and ... Bayer announced today that it,has elected to temporarily ... results from the Canadian BART trial can,be compiled, ...
... NATICK, Mass., Nov. 5 Boston Scientific,Corporation (NYSE: ... for the sale of its Cardiac Surgery and Vascular ... healthcare equipment,and systems. The transaction will be for a ... within the next 45-90 days, subject to regulatory,approvals and ...
... Funds But Many Fund,Trustees Say They Won,t Do Business With ... ... 5 More than five,hundred attendees at the International Foundation ... in the,opening hours of the convention on Sunday carrying bags ...
... TARRYTOWN, N.Y., Nov. 5 EpiCept Corporation,(Nasdaq: ... financial,results for the three and nine months ended September ... a net loss attributable to common,stockholders of $7.7 million, ... million, or $0.22 per basic and diluted share, for ...
... simplified treatment choices led to better outcomes, research ... Simplify. Simplify. Simplify. , New research shows this ... blood pressure, which is the leading risk factor ... to the future" approach to treating hypertension helped ...
... better when the dark delight is consumed, study suggests , ... A Japanese study finds that flavonoid-rich dark chocolate can improve ... as coronary flow velocity reserve (CFVR), an indicator of the ... blood flow in response to medications. , The two-week trial ...
Cached Medicine News:Health News:Bayer Temporarily Suspends Global Trasylol(R) Marketing 2Health News:Bayer Temporarily Suspends Global Trasylol(R) Marketing 3Health News:Bayer Temporarily Suspends Global Trasylol(R) Marketing 4Health News:Boston Scientific Announces Sale of Cardiac Surgery and Vascular Surgery Businesses 2Health News:Boston Scientific Announces Sale of Cardiac Surgery and Vascular Surgery Businesses 3Health News:Boston Scientific Announces Sale of Cardiac Surgery and Vascular Surgery Businesses 4Health News:Hundreds of Benefit Fund Trustees Question Viability of Rite Aid Pharmacy Benefit Management Company 2Health News:Hundreds of Benefit Fund Trustees Question Viability of Rite Aid Pharmacy Benefit Management Company 3Health News:Hundreds of Benefit Fund Trustees Question Viability of Rite Aid Pharmacy Benefit Management Company 4Health News:EpiCept Corporation Reports Third Quarter 2007 Operating and Financial Results 2Health News:EpiCept Corporation Reports Third Quarter 2007 Operating and Financial Results 3Health News:EpiCept Corporation Reports Third Quarter 2007 Operating and Financial Results 4Health News:EpiCept Corporation Reports Third Quarter 2007 Operating and Financial Results 5Health News:EpiCept Corporation Reports Third Quarter 2007 Operating and Financial Results 6Health News:EpiCept Corporation Reports Third Quarter 2007 Operating and Financial Results 7Health News:EpiCept Corporation Reports Third Quarter 2007 Operating and Financial Results 8Health News:EpiCept Corporation Reports Third Quarter 2007 Operating and Financial Results 9Health News:EpiCept Corporation Reports Third Quarter 2007 Operating and Financial Results 10Health News:New Measures Improve Heart Care 2Health News:New Measures Improve Heart Care 3Health News:New Measures Improve Heart Care 4Health News:Chocolate Has Sweet Effect on Blood Flow 2
(Date:7/30/2015)... 2015 P&S Market ... market overview, trends, DRO analysis, market segmentation, ... developments, competitive scenario and top competitor profiles ... Market Development and Demand Forecast to 2020  ... Explore more about global biosensors ...
(Date:7/30/2015)... , July 30, 2015   Gaumard® ... update to UNI®, the world,s first operating system ... is now available exclusively to Gaumard users. UNI® ... recently launched Newborn Tory™ S2200, as well as ... monitoring of clinical measures such as EtCO 2 ...
(Date:7/30/2015)... 30, 2015   Sentrian , the Remote ... hospitalization, recently received confirmation from the Food & ... (RPI) solution meets the definition of a "medical ... "Enforcement Discretion." The designation identifies ... FDA regulatory requirements at this time" and clears ...
Breaking Medicine Technology:Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 3Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 4Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 5Gaumard's Latest UNI Operating System Update Adds Performance and New Functionality 2Gaumard's Latest UNI Operating System Update Adds Performance and New Functionality 3FDA Clears Way for Commercial Marketing of Sentrian Remote Patient Intelligence Solution 2FDA Clears Way for Commercial Marketing of Sentrian Remote Patient Intelligence Solution 3
... , New England Journal of Medicine Publishes First ... Kidney Disease Patients "Superior" in Treating Blocked Access ... A randomized multicenter study of 190 patients at 13 ... grafts over balloon angioplasty for maintaining function of dialysis access ...
... SIGNAL HILL, Calif. , Feb. 11 Integrated ... care, announced that former United States Air Force Surgeon General ... Board of Advisors. , As U.S. Air Force Surgeon General, ... Secretary of the Air Force, and provided direction to over ...
Cached Medicine Technology:Stent Grafts Top "Gold Standard" Balloon Angioplasty for Dialysis Patients 2Stent Grafts Top "Gold Standard" Balloon Angioplasty for Dialysis Patients 3Stent Grafts Top "Gold Standard" Balloon Angioplasty for Dialysis Patients 4Stent Grafts Top "Gold Standard" Balloon Angioplasty for Dialysis Patients 5Stent Grafts Top "Gold Standard" Balloon Angioplasty for Dialysis Patients 6Former Air Force Surgeon General Joins Integrated Medical Systems' Advisory Board 2Former Air Force Surgeon General Joins Integrated Medical Systems' Advisory Board 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: